Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
NCT06522997 · View on ClinicalTrials.gov ↗
Study Summary
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), CKD is a condition in which the kidneys' ability to work properly gradually decreases over time. A common sign of decreasing kidney function is the body losing too much of a protein called albumin in the urine. This condition is known as albuminuria. This can lead to a faster decline in kidney function. People who have high blood pressure and diabetes are more likely to have CKD and are at a higher risk of complications related to it. BAY3283142 is a new drug that is being developed to treat people with CKD. It works by activating a protein that helps relax blood vessels and is thought to have beneficial effects in CKD. In this study, researchers want to learn about how well different doses of BAY3283142 work when taken with standard treatment for CKD in reducing albumin in the urine of participants with CKD. They will compare the results of the change in the urine albumin-creatinine ratio (UACR) after 16 weeks for BAY3283142 with a placebo. A placebo looks like the study drug but does not have any medicine in it. During the study, participants will take either of the following drugs: * BAY3283142: Participants will take BAY3283142 as tablets by mouth. * Placebo: Participants will take it in the same way as BAY3283142. Participants will continue taking the available standard treatment for CKD and other conditions they may have (for example, heart conditions and diabetes). At the start of this study, the researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the participants. Researchers will take urine and blood samples from the participants at different time points to measure UACR and eGFR. Participants will be divided equally into different groups. Only 1 group will receive placebo and the other groups will receive BAY3283142. Participants will take their assigned treatment f
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BAY3283142
Study Locations (20)
Florida
- Nova Clinical Research - Blake Medical Center — Bradenton
- Renstar Medical Research - Deerwood Clinic — Ocala
- Elixia Central Florida — Orlando
- Florida Institue for Clinical Research — Orlando
California
- Balboa Research SMO+ - Chula Vista - West — Chula Vista
- Balboa Research SMO+ - La Mesa — La Mesa
- California Kidney Specialists - San Dimas — San Dimas
North Carolina
- Triad Internal Medicine - Asheboro — Asheboro
- Eastern Nephrology Associates - New Bern — New Bern
- Brookview Hills Research Associates, LLC — Winston-Salem
Texas
- Renal Disease Research Institute | Landry — Dallas
- Southwest Houston Research, Ltd. — Houston
- Clinical Advancement Center, PLLC — San Antonio
Illinois
- Research by Design, LLC | Chicago, IL — Chicago
- Nephrology Associates of Northern Illinois and Indiana - Hinsdale — Hinsdale
Tennessee
- Knoxville Kidney Center, PLLC — Knoxville
- Vanderbilt University Medical Center — Nashville
Alabama
- Nephrology Consultants, LLC — Huntsville
Connecticut
- Yale University School of Medicine — New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2026-03-17 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06522997
The ClinicalTrials.gov registry entry for NCT06522997 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 143 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06522997 reports 20 study locations spanning 9 distinct geographic areas — top geographies include Florida, California, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06522997 about?
NCT06522997 is a clinical study titled "A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease". Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), CKD is a condition in which the kidneys' ability to work properly gradually decreases over time. A common sign of decreasing kidney function is the body losing too much of a protein called albumin in the ...
What is the current status of trial NCT06522997?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 700 participants. The study started on 2024-08-08. Estimated completion is 2026-03-17.
What conditions does trial NCT06522997 study?
This clinical trial studies the following conditions: Chronic Kidney Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06522997?
The interventions under investigation include: Placebo (DRUG), BAY3283142 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06522997?
This trial is sponsored by Bayer, which has 143 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06522997 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.